top of page

The Only CDK4 & 6 Inhibitor Approved Across HR+, HER2- MBC

Tue, Mar 19

|

Mistral

This program will present efficacy and safety data for Verzenio, a CDK4 & 6 inhibitor approved in combination with fulvestrant, in combination with an Al, and as a single agent for HR+, HER2- advanced or MBC.

Registration is Closed
See other events
The Only CDK4 & 6 Inhibitor Approved Across HR+, HER2- MBC
The Only CDK4 & 6 Inhibitor Approved Across HR+, HER2- MBC

Time & Location

Mar 19, 2019, 6:00 PM

Mistral, 223 Columbus Ave, Boston, MA 02116, USA

Guests

About The Event

Speaker

Yelena Novik, MD

Associate Professor Medical Oncology

NYU Langone

Program Description

This program will present efficacy and safety data for Verzenio, a CDK4 & 6 inhibitor approved in combination with fulvestrant, in combination with an Al, and as a single agent for HR+, HER2- advanced or MBC.

Share This Event

BONS logo.png

Contact:

Daunielle Ricardi, President

Alissa Gentile, Treasurer

Cameron Keith, Social Media Coordinator

Email: BonsSocialMedia@gmail.com

  • Facebook
  • Instagram
  • LinkedIn
Earthen Media-4.png
bottom of page